PANP25: Spotlight on IL-13: Long-Term Strategies in the Management of Moderate-to-Severe Atopic Dermatitis: An Online Activity

PANP25: Spotlight on IL-13: Long-Term Strategies in the Management of Moderate-to-Severe Atopic Dermatitis: An Online Activity

This 45-minute symposium from the 2025 Fall Clinical Dermatology Conference for PAs and NPs throws a spotlight on the long-term use of IL-13 targeted biologic therapies in mitigating the chronicity of itch and other symptoms of moderate-to-severe atopic dermatitis.

“When do you use systemic therapy? Many of us think of 10% BSA, that’s what the trials did… But I really encourage you to look beyond BSA, look at the quality of life of the patient, look at where the disease is at. Is it in a special area, a high impact area? Have they failed topicals for many years? Really, you need to look at using systemic therapy beyond that 10%.” – Dr. Andrew Blauvelt

This activity is supported by an educational grant from Lilly USA, LLC.